# Cannabidiol in Sickle Cell Disease

> **NCT06930703** · PHASE1,PHASE2 · RECRUITING · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 52 (estimated)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Cannabidiol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06930703
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-03
- **Primary completion:** 2027-02-01
- **Final completion:** 2027-02-01
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06930703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06930703, "Cannabidiol in Sickle Cell Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06930703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*